MDM2 amplification in a real-world cohort of patients with biliary tract cancer from the Spanish RETUD gastrointestinal registry
Incidence of <i>MDM2</i> amplification was similar to that described in other BTC cohorts. Comparable results in demographic/clinical characteristics, molecular profile, and survival outcomes between patients with/without <i>MDM2</i> amplification was observed.
Authors
- R.M. Rodríguez-Alonso
- Laura Ortega (ORCID: https://orcid.org/0000-0003-0456-7322)
- Teresa Macarulla (ORCID: https://orcid.org/0000-0002-1881-362X)
- P. Peinado
- M. Lobo de Mena
- Susana Aguilar
- Florian Castet (ORCID: https://orcid.org/0000-0002-5416-5383)
- Andrés Jesús Muñoz Martín (ORCID: https://orcid.org/0000-0001-6977-8249)
- Jorge Adeva (ORCID: https://orcid.org/0000-0002-3959-4120)
- Javier Soto Alsar (ORCID: https://orcid.org/0009-0009-8859-5881)
- Sonia Vega
- I. Alés Díaz
- Ruth Vera (ORCID: https://orcid.org/0000-0003-1524-3147)
- Inmaculada Ruiz de Mena (ORCID: https://orcid.org/0000-0001-7440-9309)
Institutions
- Hospital General Universitario Gregorio Marañón (ES)
- Research Institute Hospital 12 de Octubre (ES)
- Instituto Maimónides de Investigación Biomédica de Córdoba (ES)
- Hospital Universitario 12 De Octubre (ES)
- HM Hospitales (ES)
- Hospital Universitario Reina Sofía (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital General Universitario De Valencia (ES)
- Spanish Head & Neck Cancer Cooperative Group (ES)
- Complejo Hospitalario de Pontevedra (ES)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1016/j.esmogo.2025.100187
- Citations
- 1
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- AstraZeneca
- Incyte